In the third observational prospective study by Huser et al., 108 HL patients, treated between 2005 and 2010 with different CT regimens (6–8 cycles of eBEACOPP or 2 cycles of ABVD or 2 cycles of eBEACOPP, followed by 2 cycles of ABVD) also received monthly triptorelin injections and had a mean FSH level of 11.6 ± 17.9 IU/L after one year from the end of treatment [48]. This evidence concerns the gene BRD2 and Hodgkins lymphoma.